ISIS-APO(a)Rx

a 2'-O-(2-methoxyethyl)-modified antisense nucleotide for inhibiting apolipoprotein A synthesis

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

1.	Aortic Valve Stenosis (Aortic Stenosis) 03/01/2016 - "ISIS-APO(a)Rx represents the first specific and potent drug in clinical development to lower Lp(a) levels and may be beneficial in reducing CVD events and progression of calcific aortic valve stenosis. " 10/10/2015 - "The safety and tolerability support continued clinical development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular disease and calcific aortic valve stenosis in patients with elevated Lp(a) concentration. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 10/10/2015 - "The safety and tolerability support continued clinical development of ISIS-APO(a)Rx as a potential therapeutic drug to reduce the risk of cardiovascular disease and calcific aortic valve stenosis in patients with elevated Lp(a) concentration. "